As the number of biological product approvals has increased significantly over the past 20 years—and as Japanese health authorities have worked to reduce drug prices and encourage generic drug development--we can expect to see an increase in the development of biosimilars in the country.
This paper examines the overall healthcare market and trends in biosimilar drug development in Japan and provides strategies and key considerations for developers seeking to market these products in the country.
Download the white paper.
